<?xml version='1.0' encoding='utf-8'?>
<document id="30107284"><sentence text="Contraindicated drug-drug interactions associated with oral antimicrobial agents prescribed in the ambulatory care setting in the United States." /><sentence text="Antimicrobial agents are commonly used in ambulatory care settings" /><sentence text=" Our objective was to examine national-level patterns of contraindications between oral antibacterial or antifungal agents and patients' other oral medications in the US ambulatory care setting" /><sentence text="" /><sentence text="This cross-sectional study included multiple year pooled data (2003-2011) from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey (NHAMCS Outpatient Department)" /><sentence text=" Visits by adults (age ≥18 years) in ambulatory settings in the United States who were prescribed oral antibacterial or antifungal agents were evaluated for potential drug-drug interaction (DDI) contraindications" /><sentence text=" Findings with relative standard error &gt;30% or unweighted sample size &lt;30 were not reported because these were deemed unreliable estimates" /><sentence text="" /><sentence text="From 2003 to 2011, there were 1 235 000 outpatient visits (proportion = 0" /><sentence text="52%; 95% confidence interval (CI), 0" /><sentence text="29-0" /><sentence text="74) in which a patient was prescribed an antimicrobial agent associated with a contraindicated DDI" /><sentence text=" The most prevalent antimicrobials with contraindicated combination among outpatients were simultaneous use of macrolide-containing products (erythromycin or clarithromycin) with statin medication-containing products (simvastatin or lovastatin) (841 864 visits, proportion = 1"><entity charOffset="111-120" id="DDI-PubMed.30107284.s13.e0" text="macrolide" /><entity charOffset="142-154" id="DDI-PubMed.30107284.s13.e1" text="erythromycin" /><entity charOffset="158-172" id="DDI-PubMed.30107284.s13.e2" text="clarithromycin" /><entity charOffset="218-229" id="DDI-PubMed.30107284.s13.e3" text="simvastatin" /><entity charOffset="233-243" id="DDI-PubMed.30107284.s13.e4" text="lovastatin" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e0" e2="DDI-PubMed.30107284.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e0" e2="DDI-PubMed.30107284.s13.e1" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e0" e2="DDI-PubMed.30107284.s13.e2" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e0" e2="DDI-PubMed.30107284.s13.e3" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e0" e2="DDI-PubMed.30107284.s13.e4" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e1" e2="DDI-PubMed.30107284.s13.e1" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e1" e2="DDI-PubMed.30107284.s13.e2" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e1" e2="DDI-PubMed.30107284.s13.e3" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e1" e2="DDI-PubMed.30107284.s13.e4" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e2" e2="DDI-PubMed.30107284.s13.e2" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e2" e2="DDI-PubMed.30107284.s13.e3" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e2" e2="DDI-PubMed.30107284.s13.e4" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e3" e2="DDI-PubMed.30107284.s13.e3" /><pair ddi="false" e1="DDI-PubMed.30107284.s13.e3" e2="DDI-PubMed.30107284.s13.e4" /></sentence><sentence text="91%; 95% CI, 0"><entity charOffset="9-11" id="DDI-PubMed.30107284.s14.e0" text="CI" /></sentence><sentence text="96-2" /><sentence text="86)" /><sentence text=" The next most common combination was use of fluoroquinolones with antiarrhythmic agents (amiodarone, sotalol, quinidine or procainamide) (365 622 visits, proportion = 0"><entity charOffset="45-61" id="DDI-PubMed.30107284.s17.e0" text="fluoroquinolones" /><entity charOffset="90-100" id="DDI-PubMed.30107284.s17.e1" text="amiodarone" /><entity charOffset="102-109" id="DDI-PubMed.30107284.s17.e2" text="sotalol" /><entity charOffset="111-120" id="DDI-PubMed.30107284.s17.e3" text="quinidine" /><entity charOffset="124-136" id="DDI-PubMed.30107284.s17.e4" text="procainamide" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e0" e2="DDI-PubMed.30107284.s17.e0" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e0" e2="DDI-PubMed.30107284.s17.e1" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e0" e2="DDI-PubMed.30107284.s17.e2" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e0" e2="DDI-PubMed.30107284.s17.e3" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e0" e2="DDI-PubMed.30107284.s17.e4" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e1" e2="DDI-PubMed.30107284.s17.e1" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e1" e2="DDI-PubMed.30107284.s17.e2" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e1" e2="DDI-PubMed.30107284.s17.e3" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e1" e2="DDI-PubMed.30107284.s17.e4" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e2" e2="DDI-PubMed.30107284.s17.e2" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e2" e2="DDI-PubMed.30107284.s17.e3" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e2" e2="DDI-PubMed.30107284.s17.e4" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e3" e2="DDI-PubMed.30107284.s17.e3" /><pair ddi="false" e1="DDI-PubMed.30107284.s17.e3" e2="DDI-PubMed.30107284.s17.e4" /></sentence><sentence text="19%; 95% CI, 0"><entity charOffset="9-11" id="DDI-PubMed.30107284.s18.e0" text="CI" /></sentence><sentence text="06-0" /><sentence text="32)" /><sentence text="" /><sentence text="Providers should be aware of potential contraindicated DDIs when prescribing antibiotics, especially macrolides and fluoroquinolones" /><sentence text="" /></document>